Moleculin Biotech
MBRX
15 hedge funds and large institutions have $4.44M invested in Moleculin Biotech in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1,254% more capital inflows, than outflows
Capital inflows: $1.86M | Capital outflows: $137K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
15% more funds holding
Funds holding: 13 → 15 (+2)
10.17% more ownership
Funds ownership: 7.22% → 17.39% (+10%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$1.78M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$37.4K |
| 3 |
Atticus Wealth Management
Palm Beach Gardens,
Florida
|
+$29.1K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$12.5K |
| 5 |
Renaissance Technologies
New York
|
+$4.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sio Capital Management
New York
|
-$116K |
| 2 |
Millennium Management
New York
|
-$13K |
| 3 |
BlackRock
New York
|
-$4.15K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$4.15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$85 |
MBRX Hedge Fund Activity: Q4 2023 in Review
15 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2023, worth a combined $4.44M — up 380% from $925K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MBRX positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.78M. The largest seller was Sio Capital Management, exiting entirely with an estimated $116K sold.
- 15 institutional investors held Moleculin Biotech (MBRX) as of Q4 2023, up from 13 in Q3 2023.
- Funds reported $4.44M of Moleculin Biotech stock for Q4 2023, up 380% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q4 2023 and 2 closed out, a net change of +2 holders.
- The largest Moleculin Biotech buyer in Q4 2023 was Armistice Capital, an estimated $1.78M added.
- The largest Moleculin Biotech seller in Q4 2023 was Sio Capital Management, an estimated $116K sold.
Based on aggregated 13F filings for Q4 2023.